New antibiotic candidate VNRX-7145 gets first safety check in humans
NCT ID NCT04243863
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety of a new drug, VNRX-7145, in 83 healthy adults aged 18 to 45. Participants received either a single dose or multiple doses over 10 days to see how the body handles the drug and if any side effects occur. The study is complete and focused only on safety and drug levels, not on treating any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VNRX-7145
- What could go wrong
- This is an early-stage trial in healthy volunteers, not patients. It only measures safety and drug levels, not whether the drug works against any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Worldwide Clinical Trials Early Phase Services, LLC
San Antonio, Texas, 78217, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults